Trelegy Ellipta is a maintenance treatment for patients with asthma and COPD. "The FDA's acceptance of our ANDA filing for ...

GlaxoSmithKline’s latest earnings call struck an upbeat tone, with management emphasizing broad‑based momentum in specialty medicines, vaccines and late‑stage R&D, even as legacy general medicines and ...

YUPELRI® Collaboration Revenue increased 15% year-over-year1, from $15.4 million to $17.7 million, driven by continued Net Sales growth and improved operating leverage ...

Portfolio Receipts growth of 10% to $925 million; Royalty Receipts growth of 13%Net cash provided by operating activities of $718 millionRaised ...

Earnings season is in full swing, and on April 29, three Big Pharma mainstays reported Q1 2026 earnings. Investors were ...

Earnings call GSK delivered a strong Q1 2026 with sales up 5% YoY to over GBP 7.6 billion, driven by Specialty Medicines (+14%) and record Shingrix sales (+20%). Core operating profit rose 10%, EPS ...

Strong first-quarter results under new GSK CEO Luke Miels on Wednesday failed to impress investors, who raised concerns ‌that the British drugmaker's performance was enhanced by one-off factors, ...

GSK has finally called time on its pact with Mersana Therapeutics despite sinking $100 million to secure an option for an antibody-drug conjugate (ADC). That deal, signed back in 2022, centered on XMT ...

More than 20 years after gaining FDA approval for Flovent, GSK still controlled the market in the U.S. for the asthma inhaler through a partnership with an “authorized generic” dealer, a setup that ...

Transpire Bio Inc. was hit with a patent infringment lawsuit on March 6 in Florida Southern District Court. The lawsuit, brought by Nelson Mullins Riley & Scarborough and Wilmer Cutler Pickering Hale ...

A Theravance researcher at work. Theravance Biopharma said it is chopping its workforce by 50% and launching a review of strategic alternatives designed to maximize shareholder value, after its sole ...

GSK struck a $950 million deal to buy Canada’s 35Pharma, a biopharmaceutical company developing cardiopulmonary treatments, as the U.K. drugmaker seeks to bolster its exposure to diseases linked to ...